Long Term Outcome of Immunoglobulin A (IgA) Nephropathy: A Single Center Experience

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Apr 8

PMID 33831052

Citations 9

Authors

Rozita Mohd

Nur Ezzaty Mohammad Kazmin

Rizna Abdul Cader

Nordashima Abd Shukor

Yin Ping Wong

Shamsul Azhar Shah

Nurwardah Alfian

Affiliations

Soon will be listed here.

Abstract

Introduction: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and the factors affecting it.

Methods: This study included all biopsy-proven IgAN patients with ≥ 1year follow-up. Patients with diabetes mellitus at diagnosis and secondary IgAN were excluded. Medical records were reviewed for demographics, clinical presentation, blood pressure, 24-hour urine protein, serum creatinine, renal biopsy and treatment received. The primary outcome was defined as combined event of 50% estimated glomerular filtration rate (eGFR) reduction or ESRD.

Results: We included 130 (74 females; 56 males) patients of mean age 38.0 ± 14.0 years and median eGFR of 75.2 (interquartile range (IQR) 49.3-101.4) ml/min/1.73m2. Eighty-four (64.6%) were hypertensive at presentation, 35 (26.9%) had nephrotic syndrome and 57 (43.8%) had nephrotic range proteinuria (NRP). Median follow-up duration was 7.5 (IQR 4.0-13.0) years. It was noted that 18 (13.8%) developed ESRD and 34 (26.2%) reached the primary outcome. Annual eGFR decline was -2.1 (IQR -5.3 to -0.1) ml/min/1.73m2/year, with median survival of 20 years. Survival rates from the combined event (50% decrease in eGFR or ESRD) at 10, 20 and 30 years were 80%, 53% and 25%, while survival from ESRD were 87%, 73% and 65%, respectively. In the univariate analysis, time-average proteinuria (hazard ratio (HR) = 2.41, 95% CI 1.77-3.30), eGFR <45ml/min/1.73m2 at biopsy (HR = 2.35, 95% CI 1.03-5.32), hypertension (HR = 2.81, 95% CI 1.16-6.80), mean arterial pressure (HR = 1.02, 95% CI 1.01-1.04), tubular atrophy/interstitial fibrosis score (HR = 3.77, 95% CI 1.84-7.73), and cellular/fibrocellular crescent score (HR = 2.44, 95% CI 1.19-5.00) were found to be significant. Whereas only time-average proteinuria (TA-proteinuria) remained as a significant predictor in the multivariate analysis (HR = 2.23, 95% CI 1.57-3.16).

Conclusion: In our cohort, TA-proteinuria was the most important predictor in the progression of IgAN, irrespective of degree of proteinuria at presentation.

Citing Articles

Blood and urine biomarkers of disease progression in IgA nephropathy.

Duan Z, Zhang C, Chen X, Cai G Biomark Res. 2024; 12(1):72.

PMID: 39075557 PMC: 11287988. DOI: 10.1186/s40364-024-00619-4.

Clinical and Epidemiological Study of IgA Nephropathy in the Bulgarian Population: Insights into Disease Presentation and Potential Biomarkers.

Kostadinova I, Lyubomirova M, Bogov B, Kurteva E, Kyurkchiev D, Todorov T J Pers Med. 2024; 14(3).

PMID: 38541011 PMC: 10970904. DOI: 10.3390/jpm14030269.

Sagi B, Vas T, Csiky B, Nagy J, Kovacs T J Clin Med. 2024; 13(4).

PMID: 38398303 PMC: 10889748. DOI: 10.3390/jcm13040991.

The predictive value and response to immunosuppressive therapy of IgA nephropathy patients with crescents in a large retrospective Chinese cohort.

Guo Y, Shi S, Zhou X, Liu L, Lv J, Zhu L Clin Kidney J. 2023; 16(12):2417-2428.

PMID: 38046023 PMC: 10689141. DOI: 10.1093/ckj/sfad134.

Detection of N‑glycoprotein associated with IgA nephropathy in urine as a potential diagnostic biomarker using glycosylated proteomic analysis.

Liu J, Wu L, Gu H, Lu M, Zhang J, Zhou H Exp Ther Med. 2023; 26(4):478.

PMID: 37753295 PMC: 10518647. DOI: 10.3892/etm.2023.12177.

References

Nam K, Kie J, Lee M, Chang T, Wha Kang E, Kim D . Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One. 2014; 9(7):e101935. PMC: 4086982. DOI: 10.1371/journal.pone.0101935. View

Koyama A, Igarashi M, Kobayashi M . Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997; 29(4):526-32. DOI: 10.1016/s0272-6386(97)90333-4. View

Barbour S, Cattran D, Kim S, Levin A, Wald R, Hladunewich M . Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013; 84(5):1017-24. DOI: 10.1038/ki.2013.210. View

Reich H, Troyanov S, Scholey J, Cattran D . Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12):3177-83. DOI: 10.1681/ASN.2007050526. View

Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S . Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008; 12(1):1-8. DOI: 10.1007/s10157-007-0010-9. View

Coppo R, DAmico G . Factors predicting progression of IgA nephropathies. J Nephrol. 2005; 18(5):503-12. View

Katafuchi R, Oh Y, Hori K, Komota T, Yanase T, Ikeda K . An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol. 1994; 41(4):191-8. View

Han X, Xiao Y, Tang Y, Zheng X, Anwar M, Qin W . Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome. Clin Exp Med. 2019; 19(4):479-486. DOI: 10.1007/s10238-019-00580-9. View

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B . Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015; 373(23):2225-36. DOI: 10.1056/NEJMoa1415463. View

10.

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M . After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; 98(4):1044-1052. DOI: 10.1016/j.kint.2020.04.046. View

11.

Knoop T, Vikse B, Mwakimonga A, Leh S, Bjorneklett R . Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant. 2017; 32(11):1841-1850. DOI: 10.1093/ndt/gfx242. View

12.

Gowrishankar S, Gupta Y, Vankalakunti M, Gowda K, Kurien A, Jansi Prema K . Correlation of Oxford MEST-C Scores With Clinical Variables for IgA Nephropathy in South India. Kidney Int Rep. 2019; 4(10):1485-1490. PMC: 6829187. DOI: 10.1016/j.ekir.2019.06.013. View

13.

Jiang L, Dong B, Yan Y, Zheng S, Hu Y, Zuo L . Clinicopathological analysis of IgA nephropathy combined with other glomerular diseases. Medicine (Baltimore). 2019; 98(41):e17388. PMC: 6799395. DOI: 10.1097/MD.0000000000017388. View

14.

Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H . Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014; 9(3):e91756. PMC: 3962373. DOI: 10.1371/journal.pone.0091756. View

15.

Thompson A, Carroll K, Inker L, Floege J, Perkovic V, Boyer-Suavet S . Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019; 14(3):469-481. PMC: 6419287. DOI: 10.2215/CJN.08600718. View

16.

Bartosik L, Lajoie G, Sugar L, Cattran D . Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001; 38(4):728-35. DOI: 10.1053/ajkd.2001.27689. View

17.

Ma F, Liu L, Dong R, Yang X, Wei L, Li L . Renal survival and risk factors in IgA nephropathy with crescents. Int Urol Nephrol. 2020; 52(8):1507-1516. DOI: 10.1007/s11255-020-02457-3. View

18.

Rodrigues J, Haas M, Reich H . IgA Nephropathy. Clin J Am Soc Nephrol. 2017; 12(4):677-686. PMC: 5383386. DOI: 10.2215/CJN.07420716. View

19.

Kang S, Choi S, Park H, Lee J, Sun I, Hwang H . The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2011; 27(1):252-8. DOI: 10.1093/ndt/gfr295. View

20.

Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C . The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011; 6(10):2384-8. PMC: 3359557. DOI: 10.2215/CJN.01170211. View